JHVEPhoto
Teva Pharmaceutical (NYSE:TEVA) and Alvotech (NASDAQ:ALVO) have launched their biosimilar targeting Johnson & Johnson’s (NYSE:JNJ) blockbuster arthritis therapy Stelara (ustekinumab) in the U.S. weeks after Amgen (NASDAQ:AMGN) became the first to launch a Stelara copycat version.
Teva (NYSE:TEVA) and